Does administration of hydroxychloroquine/amiodarone affect the efficacy of enzyme replacement therapy for Fabry mice?
© 2024 The Authors..
As a standard therapy for Fabry disease, enzyme replacement therapy (ERT) with recombinant human α-galactosidase A (α-Gal) has been successfully used, and the instructions for this drug state that "it should not be co-administrated with cationic amphiphilic drugs such as hydroxychloroquine (HCQ) and amiodarone (AMI), since these drugs have the potential to inhibit intracellular α-Gal activity". However, there would be cases in which HCQ or AMI is required for patients with Fabry disease, considering their medical efficacy and application. Thus, we examined the impact of HCQ/AMI on recombinant human α-Gal by in vitro, cellular, and animal experiments. The results revealed that HCQ/AMI affected the enzyme activity of α-Gal incorporated into cultured fibroblasts from a Fabry mouse when the cells were cultured in medium containing these drugs and the enzyme, although their direct inhibitory effect on the enzyme is not strong. These lysosomotropic drugs may be trapped and concentrated in lysosomes, followed by inhibition of α-Gal. On the other hand, no reduction of α-Gal activity incorporated into the organs and tissues, or acceleration of glycoshingolipid accumulation was observed in Fabry mice co-administered with HCQ/AMI and the enzyme, compared with in the case of usual ERT. As HCQ/AMI administered are catabolized in the liver, these drugs possibly do not affect ERT for Fabry mice, different from in the case of cultured cells in an environment isolated from the surroundings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Molecular genetics and metabolism reports - 39(2024) vom: 27. Apr., Seite 101079 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tsukimura, Takahiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
α-Galactosidase A |
|---|
| Anmerkungen: |
Date Revised 25.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.ymgmr.2024.101079 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370904419 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370904419 | ||
| 003 | DE-627 | ||
| 005 | 20240425233819.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ymgmr.2024.101079 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM370904419 | ||
| 035 | |a (NLM)38601121 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tsukimura, Takahiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Does administration of hydroxychloroquine/amiodarone affect the efficacy of enzyme replacement therapy for Fabry mice? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a As a standard therapy for Fabry disease, enzyme replacement therapy (ERT) with recombinant human α-galactosidase A (α-Gal) has been successfully used, and the instructions for this drug state that "it should not be co-administrated with cationic amphiphilic drugs such as hydroxychloroquine (HCQ) and amiodarone (AMI), since these drugs have the potential to inhibit intracellular α-Gal activity". However, there would be cases in which HCQ or AMI is required for patients with Fabry disease, considering their medical efficacy and application. Thus, we examined the impact of HCQ/AMI on recombinant human α-Gal by in vitro, cellular, and animal experiments. The results revealed that HCQ/AMI affected the enzyme activity of α-Gal incorporated into cultured fibroblasts from a Fabry mouse when the cells were cultured in medium containing these drugs and the enzyme, although their direct inhibitory effect on the enzyme is not strong. These lysosomotropic drugs may be trapped and concentrated in lysosomes, followed by inhibition of α-Gal. On the other hand, no reduction of α-Gal activity incorporated into the organs and tissues, or acceleration of glycoshingolipid accumulation was observed in Fabry mice co-administered with HCQ/AMI and the enzyme, compared with in the case of usual ERT. As HCQ/AMI administered are catabolized in the liver, these drugs possibly do not affect ERT for Fabry mice, different from in the case of cultured cells in an environment isolated from the surroundings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Amiodarone | |
| 650 | 4 | |a Cationic amphiphilic drug | |
| 650 | 4 | |a Drug-induced phospholipidosis | |
| 650 | 4 | |a Enzyme replacement therapy | |
| 650 | 4 | |a Fabry disease | |
| 650 | 4 | |a Glycosphingolipid | |
| 650 | 4 | |a Hydroxychloroquine | |
| 650 | 4 | |a α-Galactosidase A | |
| 700 | 1 | |a Saito, Koki |e verfasserin |4 aut | |
| 700 | 1 | |a Shiga, Tomoko |e verfasserin |4 aut | |
| 700 | 1 | |a Ogawa, Yasuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Sakuraba, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Togawa, Tadayasu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular genetics and metabolism reports |d 2014 |g 39(2024) vom: 27. Apr., Seite 101079 |w (DE-627)NLM237523892 |x 2214-4269 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2024 |g day:27 |g month:04 |g pages:101079 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ymgmr.2024.101079 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2024 |b 27 |c 04 |h 101079 | ||